Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07624526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Name: Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty — clinical trial record (NCT07624526)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorEmory University

Started2026-07

View on ClinicalTrials.gov ↗

Emory University

371 trials monitored

See 23 trials at risk

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Trial Details

NCT Number	NCT07624526
Lead Sponsor	Emory University Collaborators: Vertex Pharmaceuticals Incorporated
Conditions	Knee Arthritis, Knee Osteoarthritis
Enrollment	75 participants
Start Date	2026-07
Primary Completion	2028-08 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-03